INVESTIGADORES
SANCHEZ PEÑA Ricardo Salvador
congresos y reuniones científicas
Título:
First Artificial Pancreas Clinical tests in Latin America (Plenaria)
Autor/es:
RICARDO S. SÁNCHEZ PEÑA
Lugar:
Cartagena
Reunión:
Conferencia; 3rd IEEE Colombian Conference on Automatic Control; 2017
Institución organizadora:
IEEE Control Systems Society
Resumen:
<!-- /* Font Definitions */@font-face{font-family:Cambria;panose-1:0 0 0 0 0 0 0 0 0 0;mso-font-alt:"Times New Roman";mso-font-charset:77;mso-generic-font-family:roman;mso-font-format:other;mso-font-pitch:auto;mso-font-signature:3 0 0 0 1 0;} /* Style Definitions */p.MsoNormal, li.MsoNormal, div.MsoNormal{mso-style-parent:"";margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;mso-pagination:widow-orphan;font-size:12.0pt;font-family:"Times New Roman";mso-ascii-font-family:Cambria;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Cambria;mso-fareast-theme-font:minor-latin;mso-hansi-font-family:Cambria;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:minor-bidi;}@page Section1{size:595.0pt 842.0pt;margin:72.0pt 90.0pt 72.0pt 90.0pt;mso-header-margin:35.4pt;mso-footer-margin:35.4pt;mso-paper-source:0;}div.Section1{page:Section1;}-->Charla Plenaria (invitada):Se describirán las primeras pruebas clínicas con un Páncreas Artificial realizadas en Buenos Aires en 2016 y 2017.Workshop (invitado): Control?oriented models for Artificial Pancreas algorithm designThe Artificial Pancreas (AP) is the combinationof a Continuous Glucose Monitor (CGM) with an Insulin pump connected through acontrol algorithm that maintains the blood glucose levels within normal values.It is intended for Type 1 Diabetes Mellitus (T1DM) patients that requirepermanent insulin doses to regulate their glucose levels. There are dynamicmodels designed for simulations and analysis purposes (as presented in thefirst talk) and other models that are useful for controller design. In this talksome of the control-oriented models in the technical literature will bedescribed. In particular some recent results we have in our group, that includeinter? and intra?patient variations in the model, will be presented in greaterdetail. These provide the possibility of controller design that accounts forthe uncertain time-varying nature of this problem. One of our models has beenused to design a controller for the first clinical trials with an AP in LatinAmerica.